Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Coya Therapeutics, Inc. Common Stock(COYA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for COYA
10/23/2026: COYA (1-star) is currently NOT-A-BUY. Pass it for now.
Coya Therapeutics is a clinical-stage biotechnology company focused on modulating regulatory T cells to treat neurodegenerative and autoimmune diseases. Its primary strength lies in a specialized, multi-modal biological platform and a leadership team with deep industry expertise. The company’s core growth opportunity hinges on the successful advancement of its lead candidates, such as COYA 302, through clinical trials. However, investors face significant risks, including the high failure rate of early-stage biotech, the necessity for future capital raises, and stiff competition from larger pharmaceutical incumbents. Coya is best suited for risk-tolerant growth investors, and they should closely monitor clinical data readouts and regulatory developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to clinical success but carries extreme speculative risk. |
| Momentum investor | Mixed fit | Investors may find opportunity during positive clinical data releases, though volatility is high. |
| Value investor | Weak fit | There are no traditional earnings or cash flow metrics to support a value-based valuation. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on cash-intensive R&D. |
| Low-risk investor | Weak fit | The high risk of failure in clinical-stage biotech makes this inappropriate for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical news, leading to significant price swings. |
| Valuation risk | High | Valuations are highly speculative and dependent on future, uncertain clinical outcomes. |
| Competition risk (Biopharma incumbents) | High | Well-funded competitors can out-spend and out-maneuver smaller firms in clinical development. |
| Business quality | Medium | While the science is focused, the lack of commercialized products means business quality is unproven. |
| Dividend income | Low / none | No income generation is expected in the foreseeable future. |
| Execution risk | High | Success depends entirely on the successful management and outcome of complex clinical trials. |
Price Behavior
Flat / Range-Bound
The stock price has been trading within a narrow range with minimal directional movement.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -49.45% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 92.42M USD | Price to earnings Ratio - | 1Y Target Price 15.21 |
Price to earnings Ratio - | 1Y Target Price 15.21 | ||
Volume (30-day avg) 153.3K shares | Beta 0.58 | 52 Weeks Range 3.71 - 6.77 | Updated Date 10/25/2026 |
52 Weeks Range 3.71 - 6.77 | Updated Date 10/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.07 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Research and Development | Clinical trial activities and drug development of Treg-based therapies. | The company currently spends money to develop potential future drugs rather than earning revenue. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 68.42M | Price to Sales(TTM) 11.53 |
Enterprise Value 68.42M | Price to Sales(TTM) 11.53 | ||
Enterprise Value to Revenue 161.57 | Enterprise Value to EBITDA -6.21 | Shares Outstanding 23.46M | Shares Floating 17.54M |
Shares Outstanding 23.46M | Shares Floating 17.54M | ||
Percent Insiders 14.69 | Percent Institutions 33.25 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.